Clinical Trials Logo

Clinical Trial Summary

The STOPCoV study is a decentralized study comparing COVID-19 vaccine specific antibody levels at 24 weeks after final vaccine dose. We plan to study the safety and immunogenicity of COVID-19 vaccine(s) in community dwelling persons 70 years and over relative to a younger group (aged 30 - 50 years).


Clinical Trial Description

This is a prospective observational study of a cohort of individuals aged 30-50 years and a cohort of individuals aged 70 years and over receiving the COVID-19 vaccine. Participants will complete a questionnaire to determine eligibility. Eligible participants will complete and sign an e-consent and then be provided with a participant ID, log in information and password to the database portal, and then be enrolled into the study. Participants will complete the study assessments (baseline questionnaire, post vaccine symptom e-diary monthly, check-in questionnaire and dried blood spot specimens) ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05208983
Study type Observational
Source University Health Network, Toronto
Contact
Status Active, not recruiting
Phase
Start date May 6, 2021
Completion date April 2024

See also
  Status Clinical Trial Phase
Completed NCT04560881 - Clinical Trial to Evaluate the Efficacy, Immunogenicity and Safety of the Inactivated SARS-CoV-2 Vaccine (COVID-19) Phase 3
Terminated NCT04449380 - Clinical Study for the Treatment With Interferon-ß-1a (IFNß-1a) of COVID-19 Patients Phase 2
Recruiting NCT05364268 - Evaluation of the AudibleHealth Dx AI/ML-Based Dx SaMD Using FCV-SDS in the Diagnosis of COVID-19 Illness: Clinical Validation
Not yet recruiting NCT05268679 - Covid-19 Vaccine Response in Heart Transplant Recipients
Terminated NCT04847583 - A Phase 2 Study to Evaluate Biomarker Change, Efficacy, Pharmacokinetics, Safety and Tolerability of Telacebec (Q203) in Covid-19 Patients Phase 2
Recruiting NCT04778059 - Safety and Efficacy of USB002 for Respiratory Distress Due to COVID-19 Phase 2
Terminated NCT04786808 - Risk Factors for COVID-19 Mortality
Withdrawn NCT05133635 - High-Dose Corticosteroid or Tocilizumab for Clinical Worsening of COVID-19 Phase 4
Recruiting NCT05077969 - Leidos-Enabled Adaptive Protocol (LEAP-CT) for Evaluation of Post-exposure Prophylaxis for Newly-infected COVID-19 Patients (Addendum 2) Phase 2
Active, not recruiting NCT05077332 - LEAP-CT for Treatment of COVID-19 Patients (Master Protocol) Phase 2
Not yet recruiting NCT05085574 - Leidos-Enabled Adaptive Protocol for Clinical Trials (LEAP-CT) in Hospitalized Patients With COVID-19 (Addendum 1) Phase 2
Completed NCT05371561 - Effect of PPE on Children's Fear in Dental Office N/A